Full-Time

Associate Director

Publications

Posted on 2/26/2025

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based gene-silencing therapies

Compensation Overview

$180k - $220k/yr

Pasadena, CA, USA

In Person

In-office presence required 5 days a week.

Category
Biology & Biotech (4)
, , ,
Requirements
  • Advanced scientific degree (Doctorate: PhD, PharmD, MD etc. in life sciences, medicine, or related field.
  • 3+ years of direct medical writing and publication plan leadership experience
  • Experience in a clinical or regulatory environment.
  • Experience with RightFind or other Creative Commons Licenses
  • Experience with Veeva Vault Systems
  • Well versed in GPP3, ICMJE, CONSORT publication guidelines
  • Strong understanding of scientific and medical terminology.
  • Proven track record of published medical or scientific writing in high impact journals and high tier congresses.
  • Excellent organizational and project management skills.
  • Ability to interpret and present complex data effectively.
  • Attention to detail and high level of accuracy.
  • Strong leadership, project management, interpersonal and communication skills.
  • Knowledge of regulatory submission processes and guidelines.
  • Excellent written and verbal communication skills.
  • Familiarity with clinical research processes and documentation.
  • Ability to work independently and meet tight deadlines.
  • Strong analytical and critical thinking skills.
  • Experience with statistical analysis and data interpretation.
  • Proficiency in Microsoft Office and specialized medical writing software, excellent organizational and project management skills, and the ability to translate complex scientific data into clear, user-friendly information.
Responsibilities
  • Conduct thorough research and gather data to support medical publications.
  • Translate complex scientific data into clear, user-friendly information.
  • Oversee the publications library and reference list.
  • Identify the primary audience (e.g., healthcare professionals, researchers, patients, payers).
  • Determine the key messages and themes for each document.
  • Identify appropriate journals and conferences for submission.
  • Consider the impact factor, audience, and relevance of each publication venue.
  • Establish metrics to evaluate the success of the publication plan (e.g., number of publications, citations, impact on clinical practice).
  • Regularly review and adjust the plan based on feedback and outcomes.
  • Plan, prepare, edit, and review high-quality scientific documents such as abstracts, posters, and presentations and develop manuscripts for peer-reviewed scientific journals.
  • Write and work with writers, editors, and designers to create engaging content and consistent voice.
  • Stay updated with the latest medical research and industry guidelines, GPP3, ICMJE, CONSORT.
  • Ensure all publications adhere to Arrowhead guidelines, compliance with authorship guidelines and ethical standards.
  • Work closely with healthcare professionals, researchers, and clinical research companies to ensure accuracy and clarity in medical writing.
  • Collaborate with internal medical experts and researchers to gather information.
  • Coordinate with printers and other vendors to ensure high-quality outputs.
  • Define the roles and responsibilities of each author and collaborator.
  • Create educational materials for healthcare professionals and patients, including brochures, websites, and manuals.
  • Oversee distribution of publications.
  • Collaborate with key stakeholders on medical communication strategy activities at congresses, including meeting summaries, post-meeting slide reviews.
  • Review, edit and proofread documents to ensure clarity and that they are free from errors and adhere to the appropriate style guide are thoroughly reviewed for medical accuracy and fair balance.
  • Outline the process for internal and external review and approval of documents.
  • Ensure materials are reviewed, signed off and maintain archive of approved materials within appropriate management system.
  • Participate in project planning to ensure timely delivery of documents.
  • Establish a timeline for the development, review, and submission of each document, including key milestones and deadlines.
  • Coordinate and manage multiple writing projects concurrently, ensuring deadlines are met.
  • Execute the planning, development, and production of publications.
  • Manage publication budgets.
  • Oversee and ensure execution of Congress Plan.
  • Oversee and support IIS/Grant Program.
Desired Qualifications
  • Experience in cardiometabolic or rare disease preferred, pulmonary, neurological diseases considered
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • REDEMPLO FDA approval drove $264M FQ1 2026 revenue and $30.8M profit from milestones.
  • $1B Madrigal deal for ARO-PNPLA3 provides $25M upfront plus milestones and royalties.
  • Breakthrough Therapy for plozasiran expands REDEMPLO to severe hypertriglyceridemia market.

What critics are saying

  • Madrigal out-licensing ARO-PNPLA3 eliminates internal MASH revenue by 2027.
  • Wave Life Sciences INHBE data erodes Arrowhead obesity program value in 2026.
  • Novartis and Sarepta withhold milestones if ARO-DIMER-PA fails Phase 1/2a in 2027.

What makes Arrowhead Pharmaceuticals unique

  • TRiM platform enables tissue-agnostic RNAi delivery across liver, pulmonary, and cardiometabolic diseases.
  • Pioneers dual-function siRNA like ARO-DIMER-PA targeting two genes in one molecule.
  • Targets undruggable genes via proprietary RNA chemistries for rapid, durable knockdown.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

Yahoo Finance
Mar 14th, 2026
Arrowhead swings to $30.8M profit on $264M revenue as FDA approves first drug REDEMPLO

Arrowhead Pharmaceuticals has raised $264 million in revenue for FQ1 2026, transitioning to a commercial-stage company following FDA approval of REDEMPLO (plozasiran), its first medicine for treating familial chylomicronemia syndrome. The drug also received regulatory clearance in China and Canada, with over 100 initial prescriptions in the US. The company swung to a net income of $30.8 million, compared to a $173.1 million loss in the prior year period. Revenue was boosted by a $200 million upfront payment from a collaboration with Novartis and a $200 million milestone from Sarepta Therapeutics. Arrowhead also initiated a Phase 1/2a trial for ARO-DIMER-PA, the industry's first dual-function clinical candidate targeting two genes in one molecule.

Access Market Intelligence
Feb 10th, 2026
Vanscoy Rare Pharmacy Selected as Exclusive Specialty Pharmacy Provider for Redemplo

Vanscoy Rare Pharmacy selected as exclusive specialty pharmacy provider for Redemplo. Vanscoy Rare Pharmacy, a leading specialty pharmacy focused on supporting people living with rare conditions, announced that it has been selected as the exclusive specialty pharmacy provider for Arrowhead Pharmaceuticals' Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis. With the FDA approval of Redemplo, patients will have access to a targeted treatment option designed to address the underlying cause of FCS. Through this agreement, Vanscoy Rare Pharmacy will provide patients with comprehensive support at each stage of their treatment journey with Redemplo. Arrowhead launched REDEMPLO independently in the U.S. with the OneREDEMPLO pricing model that creates one consistent price across current and potential future indications. Arrowhead is targeting approximately 5,000 healthcare professionals through personal promotion, complemented by a much broader omnichannel effort. REDEMPLO was recently approved by Health Canada's approval of REDEMPLO as a new treatment option for Canadians living with genetic or clinical FCS, giving patients, providers, and caregivers alike a convenient dosing option that can be self-administered at home with a subcutaneous injection once every three months. Pending regulatory review and approval, Arrowhead expects to potentially launch REDEMPLO later this year in select EU countries and in the UK. In Greater China, REDEMPLO will be marketed by Sanofi. #Redemplo #ArrowheadPharmaceuticals #FCS #VanscoyRarePharmacy #OneRedemplo #exclsuivespecialtypharmacy

Silence Therapeutics
Jan 22nd, 2026
Silence Therapeutics PLC - Acquisition of Minority Stake in Arrowhead

RNS Number : 6001T Silence Therapeutics PLC 09 January 2017 Acquisition of minority stake in Arrowhead Pharmaceuticals 9th January 2017 London, 9th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has acquired a stake, on-market, in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ("Arrowhead") of 6,006,359 common shares, representing 8.4% of the common share capital of Arrowhead, for a total cash consideration of $9.6 million (£7.8 million(1)), excluding transaction costs. Since the capital raise of May 2015, Silence has been actively evaluating a number of RNAi assets, including technologies within both listed and unlisted RNAi companies. Arrowhead is a US based NASDAQ listed company that develops medicines to treat intractable diseases by silencing the genes that cause them by means of a broad

Arrowhead Pharmaceuticals
Jan 22nd, 2026
Arrowhead Pharmaceuticals Closes $45 Million Private Offering - Arrowhead Pharmaceuticals, Inc.

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price […]

Investing.com
Jan 2nd, 2026
Bernstein raises Arrowhead Pharma stock price target to $35 on obesity data

Bernstein raises Arrowhead pharma stock price target to $35 on obesity data. Investing.com - Bernstein SocGen Group has raised the price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $35.00 from $17.00 while maintaining a Market Perform rating ahead of the company's upcoming obesity data update. The new target sits at the low end of analyst projections, which range from $35 to $100, according to InvestingPro data. Currently trading at $66.39, ARWR appears overvalued based on InvestingPro's Fair Value assessment. The price target adjustment reflects increases to Bernstein's severe hypertriglyceridemia (SHTG) estimates and the addition of obesity treatment potential to their valuation model. The new target represents the average of a discounted cash flow analysis to 2035 and an enterprise value to revenue multiple of 1.75x 2035 revenue. This valuation approach aligns with ARWR's current high multiples, with InvestingPro data showing an EV/EBITDA of 72.58 and a Price/Book ratio of 19.36. Bernstein noted that Arrowhead is among several companies pursuing non-incretin mechanisms to treat obesity, with the aim of reducing fat while preserving muscle. Other companies in this space include Eli Lilly, Roche, Regeneron, Scholar Rock, Wave Life Sciences, Alnylam, and Biohaven. Despite not being profitable over the last twelve months, ARWR maintains a strong financial health score of "GREAT" according to InvestingPro's comprehensive analysis, with liquid assets exceeding short-term obligations. The analyst highlighted recent data from Wave Life Sciences suggesting that INHBE, which Arrowhead is also pursuing, may be a better target than myostatin. This disclosure on December 8 generated substantial investor excitement, with Wave shares rising 150% and Arrowhead gaining 12%. Despite the price target increase, Bernstein recommends staying on the sidelines for Arrowhead's upcoming data update, suggesting approximately 20% potential movement in either direction. The firm believes shares are already pricing in substantial optimism, estimating $10-15 of obesity treatment value in the current stock price. In other recent news, Arrowhead Pharmaceuticals has launched Redemplo for Familial Chylomicronemia Syndrome, with Piper Sandler forecasting significant U.S. sales by 2026. The firm raised its price target for Arrowhead to $100, noting Redemplo's superior attributes compared to other treatments. RBC Capital also increased its price target for Arrowhead to $80, citing positive developments and early commercial traction for Redemplo, as well as optimism about upcoming trial results for the company's severe hypertriglyceridemia candidate. H.C. Wainwright set its price target at $85, praising the recently approved Redemplo label for its safety and convenience. Additionally, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Arrowhead's investigational drug plozasiran for severe hypertriglyceridemia. Arrowhead has also dosed the first subjects in a Phase 1/2a clinical trial for ARO-MAPT, targeting tauopathies such as Alzheimer's disease. This trial utilizes a new delivery system designed to cross the blood-brain barrier, showing potential in preclinical studies. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you be buying ARWR right now? ProPicks AI evaluates ARWR alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ARWR is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

INACTIVE